1
FOR IMMEDIATE RELEASE
- ---------------------

CONTACT:


Joseph W. Kaufmann                            Cindy Glynn (investor)
President and Chief Executive Officer         Susan Farley (media)
(610) 524-0188                                Dewe Rogerson
                                                    (212) 688-6840


                   KENSEY NASH ACQUIRES PATENTS RELATED TO
                         PUNCTURE CLOSURE TECHNOLOGY
              -ROYALTY RATES PAID TO KENSEY NASH WILL INCREASE-

EXTON, PA, November 13,  1997 -- Kensey Nash Corporation (Nasdaq: KNSY) today
announced that it has acquired a portfolio of puncture closure patents and
patent applications, which will result in a 33 to 50% increase in the royalties
paid to the Company for the Angio-Seal product by Sherwood-Davis & Geck, a
subsidiary of American Home Products Corporation (AHP:NYSE).

The intellectual property was acquired from two doctors, who had licensed their
inventions to AHP in 1995.  The licenses were subsequently transferred to
Sherwood-Davis & Geck, who holds a worldwide exclusive license to the acquired
patents and will continue to do so.  As a result of acquiring the patents,
Kensey Nash will be entitled to earn the royalty fees formerly paid by
Sherwood-Davis & Geck to the doctors for each Angio-Seal device sold,
commencing in 1998.

Under the terms of the agreement, Kensey Nash will pay a combination of Common
Stock and cash payments for the transfer of ownership of the patents.
Separately, Drs. Wouter M.M. Van de Moer and Rienk Rienks, inventors of the
acquired intellectual property, have agreed to join Kensey Nash's Medical
Advisory Board.

"Based on our projections, we believe that this addition to our worldwide 
patent portfolio will have a substantial impact on our bottom line," stated
Joseph W. Kaufmann, president and CEO of Kensey Nash Corporation.  "We look
forward to a long and mutually rewarding relationship with these creative and
experienced cardiologists."

"We are pleased to be a part of the growing success of not only the Angio-Seal
product, but the many innovative and exciting technologies that Kensey Nash is
developing," commented Drs. Van de Moer and Rienk Rienks.  "We look forward to
continued involvement in Kensey Nash through stock ownership and active
participation on Kensey Nash's Medical Advisory Board."

Kensey Nash is a medical device company focused on the commercialization and
continuing development of a line of absorbable medical devices for the sealing
of arterial punctures created during cardiovascular procedures.  Kensey Nash's
principal product, the Angio-Seal device, provides a safe, effective and quick
method of sealing arterial punctures and is designed to lower procedure costs
and enhance patient comfort. The 8F Angio-Seal device, the Company's primary
product, received FDA pre-market approval on September 30, 1996.  The device is
being marketed worldwide by Sherwood-Davis & Geck, a subsidiary of AHP.

Statements contained in this press release that are not historical facts are
forward-looking statements that are made pursuant to the Safe Harbor provisions
of the Private Securities Litigation Reform Act of 1995.  The Company cautions
that a number of important factors could cause the Company's actual results to
differ materially from those in the forward-looking statements including,
without limitation, AHP's ability to successfully manufacture and market the
Angio-Seal device, additional regulatory approvals, the Company's ability to
manufacture Angio-Seal components and competition from other puncture closure
devices. Results of operations in any past period should not be considered
indicative of the results to be expected for future periods.  Fluctuations in
operating results may also result in fluctuations in the price of the Common
Stock.